Imbruvica (ibrutinib) Receives 11th FDA Approval

Article Link: Imbruvica (ibrutinib) Receives 11th FDA Approval

NORTH CHICAGO, Ill., April 21, 2020 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of Imbruvica® (ibrutinib) in combination with…

Source: FDA New Drug Approvals